Загрузка...

Bosutinib in chronic myeloid leukemia: patient selection and perspectives

During recent years, the therapeutic landscape in chronic myeloid leukemia (CML) has changed significantly. Since the clinical introduction of tyrosine kinase inhibitors (TKIs) approximately 15 years ago, patients’ concerns have shifted from reduced life expectancy toward long-term toxicities of TKI...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Blood Med
Главные авторы: Isfort, Susanne, Brümmendorf, Tim H
Формат: Artigo
Язык:Inglês
Опубликовано: Dove Medical Press 2018
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5905837/
https://ncbi.nlm.nih.gov/pubmed/29695943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S129821
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!